Treatment of chronic fatigue syndrome by a Chinese herbal formula Sijunzi decoction

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
23/05/2019		[X] Protocol		
Registration date	Overall study status Completed	Statistical analysis plan		
28/05/2019		[X] Results		
Last Edited	Condition category	Individual participant data		
22/04/2024	Nervous System Diseases			

Plain English summary of protocol

Background and study aims

Chronic fatigue syndrome (CFS), also known as idiopathic chronic fatigue (ICF), is characterized by chronic disabling fatigue in the absence of an alternative diagnosis. Recent studies reported that the prevalence in UK and US fluctuates from 0.2% to 2.6%. Although not life-threatening, CFS severely impacts quality of life. Currently, there is no drug treatment approved for CFS. Therefore, complementary and alternative medicine has been considered for clinicians and patients, among which Chinese Herbal Medicine (CHM) is one of the main therapies. In Traditional Chinese Medicine (TCM), spleen deficiency is most related to lack of energy, and Sijunzi Decoction is the fundamental prescription for spleen deficiency pattern. The aim of this study is to evaluate the efficacy and safety of Sijunzi Decoction for the treatment of CFS.

Who can participate?

CFS patients aged 18-80 who meet the diagnostic criteria developed by American CDC

What does the study involve?

Participants are randomly allocated to either the Sijunzi group or the placebo group, receiving either Sijunzi Decoction or placebo (dummy treatment) twice a day for two consecutive months. The severity of fatigue symptoms is measured using a questionnaire at the start of the study, 1 month, 2 months (treatment endpoint) and 3 months (follow-up endpoint). Blood and fecal samples are also collected at the start and the end of treatment to further explore the potential mechanism.

What are the possible benefits and risks of participating?

The potential benefit is that CFS patients with spleen deficiency pattern may have improved symptoms and quality of life from Sijunzi Decoction treatment. Sijunzi Decoction has been widely used in China from ancient times. No obvious side effects were documented. Considering that Ginseng Radix et Rhizoma (renshen) is a principal ingredient, possible side effects may include high blood pressure, insomnia and hyperactivity.

Where is the study run from?

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (China)

When is the study starting and how long is it expected to run for? January 2019 to August 2021

Who is funding the study? Shanghai Three-year Action Plan for Accelerating the Development of Traditional Chinese Medicine

Who is the main contact?

1. Mr Liang Dai
yajlzs123@163.com

2. Ms Wenjun Zhou
wjzhou678@163.com

Contact information

Type(s)

Scientific

Contact name

Mr Liang Dai

Contact details

725 South Wanping Road Xuhui District Shanghai China 200032 +86 (0)2164385700 yajlzs123@163.com

Type(s)

Public

Contact name

Ms Wenjun Zhou

Contact details

725 South Wanping Road Xuhui District Shanghai China 200032 +86 (0)212164385700 wjzhou678@163.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

PZYH-DL-1.1

Study information

Scientific Title

Sijunzi decoction for chronic fatigue syndrome with spleen deficiency pattern: a randomized controlled trial

Study objectives

To evaluate the efficacy and safety of Sijunzi decoction for chronic fatigue syndrome with spleen deficiency pattern by comparing with placebo.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 25/04/2019, Ethics Committee of Longhua Hospital Affiliated Shanghai University of Traditional Chinese Medicine (3rd Floor, Building 2, 725 South Wanping Road, Xuhui District, Shanghai 200032, China; Tel: +86 (0)21 64385700 1318; Email: lhtcmirb@sina.cn), approval No. 2019LCSY020

Study design

Multi-centre double-blinded randomized placebo-controlled parallel clinical trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Chronic fatigue syndrome with spleen deficiency pattern

Interventions

Participants will be allocated to experimental or placebo arm based on the random number generated by SPSS 22.0 for Windows. Participants will be required to take the medicine twice daily for two consecutive months.

The experimental intervention is Sijunzi Decoction granules composed of four TCM herbs. One daily dosage contains 9 g Ginseng Radix et Rhizoma (Renshen), 9 g Atractylodis Macrocephalae Rhizoma (Baizhu), 9 g Poria (Fulin) and 6 g Glycyrrhizae Radix et Rhizoma Praeparata Cum Melle. The control intervention is placebo, which is comparable with Sijunzi Decoction granules in color, smell and taste.

Intervention Type

Other

Primary outcome(s)

Severity of fatigue symptoms measured using Chalder fatigue questionnaire at baseline, 1 month, 2 months (treatment endpoint) and 3 months (follow-up endpoint)

Key secondary outcome(s))

- 1. Impact of fatigue on physical function measured using SF-36 physical function at baseline, 1 month, 2 months (treatment endpoint) and 3 months (follow-up endpoint)
- 2. Quality of life measured using Euroqol Questionnaire at baseline, 1 month, 2 months (treatment endpoint) and 3 months (follow-up endpoint)
- 3. Severity of TCM spleen deficiency pattern measured using spleen deficiency scale at baseline, 1 month, 2 months (treatment endpoint) and 3 months (follow-up endpoint)
- 4. Overall health measured using clinical global impression scale at baseline, 2 months (treatment endpoint) and 3 months (follow-up endpoint)

Completion date

11/08/2021

Eligibility

Key inclusion criteria

- 1. 18-80 years old, both genders
- 2. Meet the American CDC diagnostic criteria of chronic fatigue syndrome
- 3. Meet the TCM criteria of spleen deficiency pattern
- 4. Informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

80 years

Sex

All

Total final enrolment

127

Key exclusion criteria

- 1. Combine with mental disorders
- 2. Secondary fatigue due to medications or other diseases
- 3. Combine with severe cardiovascular diseases, cerebrovascular diseases, hepatic diseases,

renal diseases, hematological disease, cancer, or other severe primary diseases

- 4. Pregnant or lactating women
- 5. Known allergy to ingredients or allergic constitution
- 6. Mental or legal disability
- 7. History of antibiotics administration in recent 1 month
- 8. Drug abuse or others

Date of first enrolment

31/07/2019

Date of final enrolment

30/11/2020

Locations

Countries of recruitment

China

Study participating centre

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

725 South Wanping Road Xuhui District Shanghai China 200032

Study participating centre

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

110 Ganhe Road Hongkou District Shanghai China 200437

Study participating centre

Sixth People's Hospital Affiliated to Shanghai Jiao Tong University

600 Yishan Road Xuhui District Shanghai China 200233

Study participating centre Shanghai Changning Tianshan Traditional Chinese Medicine Hospital

869 Loushanguan Road Changning District Shanghai China 200051

Study participating centre
Jiangyin Hospital of Traditional Chinese Medicine
130 Middle Renming Road
Jiangyin
China
214400

Sponsor information

Organisation

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

ROR

https://ror.org/016yezh07

Funder(s)

Funder type

Government

Funder Name

Shanghai Municipal Health Bureau

Alternative Name(s)

Shanghai Municipal Public Health Bureau

Funding Body Type

Government organisation

Funding Body Subtype

Local government

Location

China

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from principal investigator Prof. Guang Ji. Individual participant data that underlie the results reported in the final report will become available for sharing after deidentification. Data will be available beginning 6 months and ending 36 months following the final report publication. Researchers should provide a methodologically sound proposal to get data access. And researchers will only be allowed to use the data for the prescribed aims documented in the proposal. Proposals should be directed to Liang Dai (yajlzs123@163.com). To gain access, data requestors will need to sign a data access agreement. Further informed consent may be considered according to the study aims. The shared data will only be allowed to be used by the applicant for scientific studies. No commercial activities are allowed.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		13/04/2024	22/04/2024	Yes	No
Protocol article	protocol	01/10/2019	09/12/2019	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes